Product Description
Eslicarbazepine is used in combination with other medications to control focal (partial) seizures (seizures that involve only one part of the brain). Eslicarbazepine is in a class of medications called anticonvulsants. It works by decreasing abnormal excitement in the brain. (Sourced from: https://medlineplus.gov/druginfo/meds/a614032.html)
Mechanisms of Action: Sodium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Bulgaria | Canada | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | India | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Malta | Netherlands | Norway | Poland | Portugal | Romania | Russia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay
Approved Indications: Seizures
Known Adverse Events: Ataxia | Diplopia | Dizziness | Headache | Tremor | Vertigo
Company: Bial
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, China, France, Germany, Israel, Italy, Portugal, Spain, Sweden, United Kingdom
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Seizures
Phase 2: Epilepsy|Stroke
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BIA-2093-213 | P2 |
Completed |
Epilepsy|Stroke |
2023-09-11 |
|
| 2018-002747-29 | P2 |
Active, not recruiting |
Stroke|Epilepsy |
2021-09-26 |
|
| CTR20213418 | P3 |
Not yet recruiting |
Seizures |
None |
|
| CTR20220017 | P3 |
Not yet recruiting |
Seizures |
None |